Dr David Reynolds

Dr David Reynolds
Dr David Reynolds
AstronauTx Ltd


Presentations at Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine

Tue19  Oct10:50am(10 mins)

Session: Alzheimer’s Research UK
Room: Hall 1C

Profile of Dr David Reynolds

David Reynolds is the CEO of two Dementia Discovery Fund-created companies AstronauTx and LoQus23 Therapeutics. AstronauTx is focused on modulating the function of astrocytes to treat Alzheimer’s and other neurodegenerative diseases. LoQus23 is targeting DNA damage repair processes which are a driving force of the pathophysiology in triplet repeat diseases like Huntington’s disease. David also provides his neuroscience expertise to the DDF team as a part-time Venture Partner.

Before that David was the CSO of Alzheimer’s Research UK, for 3 years. Previously David has worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain research site head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain. David holds a PhD from University of Cambridge and is a visiting Professor at the Institute of Neurology, University College London.


Please login to send a Private Message

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021